Sugi Predict

Sugi Predict / Compounds / SCHEMBL2866080

SCHEMBL2866080

SCHEMBL2866080

Cc1nc(C(F)(F)F)ccc1CO

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TKT P29401 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ CXCR4 P61073 1/20 0.39
▸ TRPV1 Q8NER1 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ MBOAT4 Q96T53 3/20 0.37
▸ CNR1 P21554 5/20 0.37
▸ CYP3A4 P08684 2/20 0.37
▸ CYP2C9 P11712 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ PDE4B Q07343 1/20 0.36
▸ P2RX7 Q99572 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5576637 0.84 MEN1 (0.40) LMNAKDM4EMEN1KMT2A
SCHEMBL5265318 0.82 LMNA (0.40) TKTLMNANPC1RAB9AKDM4E
SCHEMBL23269412 0.82 LMNA (0.40) TKTLMNANPC1RAB9AKDM4E
SCHEMBL2870247 0.81 KDM4E (0.39) TKTLMNANPC1RAB9AKDM4E
SCHEMBL404270 0.81 KDM4E (0.39) TKTLMNANPC1RAB9AKDM4E
SCHEMBL4484041 0.81 KDM4E (0.39) TKTLMNANPC1RAB9AKDM4E
SCHEMBL21503616 0.79 KDM4E (0.38) TKTLMNANPC1RAB9AKDM4E
SCHEMBL19771944 0.79 KDM4E (0.38) TKTLMNANPC1RAB9AKDM4E
SCHEMBL3558234 0.79 MBOAT4 (0.49) LMNANPC1RAB9AKDM4ETRPV1
SCHEMBL28489701 0.78 TKT (0.35) TKTLMNATRPV1PDE4BP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230000847-A1 COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION DRAIG THERAPEUTICS LTD (GB) 2023-01-05 — — US disclosed
US-11298345-B2 Compounds that modulates AMPA receptor function UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2022-04-12 — — US disclosed
CN-110337440-B Compounds useful for inhibition of ROR-gamma-t 伊莱利利公司 2021-08-03 — — CN disclosed
US-11008336-B2 Compounds useful for inhibiting RORγt ELI LILLY AND COMPANY (US) 2021-05-18 — — US disclosed
US-20210113539-A1 COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION DRAIG THERAPEUTICS LTD (GB) 2021-04-22 — — US disclosed
EP-3589638-B1 COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T LILLY CO ELI (US) 2021-04-07 — — EP disclosed
US-20200048279-A1 COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T ELI LILLY AND COMPANY 2020-02-13 — — US disclosed
WO-2018160550-A1 COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T ELI LILLY AND COMPANY (US) 2018-09-07 — — WO disclosed
US-9868748-B2 Thiazolopyrrolidine inhibitors of ROR- γ VITAE PHARMACEUTICALS, INC. (US) 2018-01-16 — — US disclosed
EP-2838891-B1 AROMATIC RING COMPOUND AS GHRELIN O-ACYLTRANSFERASE INHIBITOR TAKEDA PHARMACEUTICALS CO (JP) 2017-08-02 — — EP disclosed
EP-1965644-A1 NOVEL HERBICIDES Syngenta Limited (GB) 2008-09-10 — — EP disclosed
EP-1891068-A1 TRIAZOLOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS Bristol-Myers Squibb Company (US) 2008-02-27 — — EP disclosed
WO-2007071900-A1 NOVEL HERBICIDES SYNGENTA LIMITED (GB) 2007-06-28 — — WO disclosed
WO-2007071900-A1 NOVEL HERBICIDES SYNGENTA LIMITED (GB) 2007-06-28 — — WO disclosed
US-20070004772-A1 Triazolopyridine cannabinoid receptor 1 antagonists BRISTOL-MYERS SQUIBB COMPANY 2007-01-04 — — US disclosed
US-20070004772-A1 Triazolopyridine cannabinoid receptor 1 antagonists BRISTOL-MYERS SQUIBB COMPANY 2007-01-04 — — US disclosed
US-20070004772-A1 Triazolopyridine cannabinoid receptor 1 antagonists BRISTOL-MYERS SQUIBB COMPANY 2007-01-04 — — US disclosed
WO-2006138734-A1 TRIAZOLOPYRIMIDINE CANNABINOID RECEPTOR 1 ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-12-28 — — WO disclosed
WO-2006138695-A1 TRIAZOLOPYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR 1 ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-12-28 — — WO disclosed
US-20060287341-A1 Triazolopyrimidine cannabinoid receptor 1 antagonists BRISTOL-MYERS SQUIBB COMPANY 2006-12-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230000847-A1 COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION GRIN1, GRM1, GRIN2A TKT 3998/4885LMNA 3412/4885NPC1 2905/4885
US-20060287341-A1 Triazolopyrimidine cannabinoid receptor 1 antagonists CNR1, CNR2, GPR68 TKT 2096/4885LMNA 4614/4885NPC1 1139/4885
US-20070004772-A1 Triazolopyridine cannabinoid receptor 1 antagonists CNR1, CNR2, TRPV1 TKT 2866/4885LMNA 4035/4885NPC1 750/4885
US-20210113539-A1 COMPOUNDS THAT MODULATES AMPA RECEPTOR FUNCTION GRIN1, GRM1, GRIN2A TKT 3998/4885LMNA 3412/4885NPC1 2905/4885
US-11008336-B2 Compounds useful for inhibiting RORγt RORB, RORC, RORA TKT 2666/4885LMNA 4604/4885NPC1 598/4885
US-20200048279-A1 COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T RORC, RORB, RORA TKT 2469/4885LMNA 4549/4885NPC1 1117/4885
US-11298345-B2 Compounds that modulates AMPA receptor function GRIN1, GRM1, GRIN2A TKT 3998/4885LMNA 3412/4885NPC1 2905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.